SynthesisJournal of substance abuse treatment2017
Quality of life as an outcome of opioid use disorder treatment: A systematic review.
Synthesis in Journal of substance abuse treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.Drug and alcohol dependence · 2021Pooled it
- Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders.Substance abuse · 2021Trial
- Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.Drug and alcohol dependence · 2020Trial
- Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.Annals of internal medicine · 2019Trial
- Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2018Trial
- Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.Journal of addiction medicineTrial
- Impacts of personal or family COVID-19 infection on health-related quality of life among patients with opioid use disorder.Journal of substance use · 2026Article
- Health-related quality of life measures as predictors for recurrent hospitalization and mortality among patients in heroin-assisted treatment.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Medical Cannabis and Psychological Well-Being in Illinois' Opioid Alternative Pilot Program.American journal of preventive medicine · 2025Article
- Daily profiles of nondrug reward and their association with daily outcomes for people in recovery from opioid use disorder: An application of latent profile analysis applied to intensive longitudinal data.Drug and alcohol dependence · 2025Article
- Neural Correlates of Metacognition Impairment in Opioid Addiction.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024Article
- Evaluating Quality of Life Changes over 12 Months Among Opiate Users from Romania and Associated Worsening Factors.Life (Basel, Switzerland) · 2024Article
- Characteristics and quality of life of people living with comorbid disorders in substance use recovery residences.Frontiers in public health · 2024Article
- Quality of life and associated factors of heroin-dependent patients receiving methadone and buprenorphine maintenance treatment.Neuropsychopharmacology reports · 2023Article
- A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder.Addiction science & clinical practice · 2023Article
- Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program.Substance abuse treatment, prevention, and policy · 2023Article
- Health-related quality of life and recovery capital among recovery residents taking medication for opioid use disorder in Texas.Frontiers in public health · 2023Article
- Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain.Journal of consulting and clinical psychology · 2022Article
- Health-related quality of life in outpatients with substance use disorder: evolution over time and associated factors.Health and quality of life outcomes · 2022Article
- Machine Learning for Predicting Risk of Early Dropout in a Recovery Program for Opioid Use Disorder.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsThe recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there is little evidence regarding health-related quality-of-life (HRQoL) outcomes in treatment programs. Measuring HRQoL represents an opportunity to consider outcomes of opioid use disorder treatment that are more patient-centered and more relevant to overall health than abstinence alone. We conducted a systematic literature review to explore the extent to which the collection of HRQoL by opioid treatment programs is documented in the treatment program literature. MATERIALS AND
methodsWe searched PubMed, Embase PsycINFO and Web of Science for papers published between 1965 and 2015 that reported HRQoL outcome measures from substance abuse treatment programs.
resultsOf the 3014 unduplicated articles initially identified for screening, 99 articles met criteria for further review. Of those articles, 7 were unavailable in English; therefore 92 articles were reviewed. Of these articles, 44 included any quality-of-life measure, 17 of which included validated HRQoL measures, and 10 supported derivation of quality-adjusted life year utility weights. The most frequently used validated measure was the Addiction Severity Index (ASI). Non-U.S. and more recent studies were more likely to include a measure of HRQoL.
conclusionsHRQoL measures are rarely used as outcomes in opioid treatment programs. The field should incorporate HRQoL measures as standard practice, especially measures that can be used to derive utility weights, such as the SF-12 or EQ-5D. These instruments provide policy makers with evidence on the impact of programs on patients' lives and with data to quantify the value of investing in opioid use disorder treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.